Tuberculosis, PulmonaryNCT07271225
Safety and Efficacy of Ear Acupuncture for Antituberculosis Drug-Related Nausea and Vomiting
A study testing Press Needle in people with Tuberculosis, Pulmonary, run by Universitas Indonesia at 1 site in Indonesia.
Trial summary
This study will look at whether press-needle ear acupuncture can help lower nausea and vomiting caused by antituberculosis medicines in people with pulmonary tuberculosis. Nausea and vomiting are common side effects of tuberculosis treatment, and they can make people stop taking their medicines When treatment is… Read more about this study
- Who is it for?
- Ages 17 years and older
- Conditions the study is for
- Tuberculosis, Pulmonary
- What is being tested?
- Press Needle
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 58 participants
- Where
- 1 siteIndonesia
- Study dates
- 5 Nov 2025to 30 Jun 2026
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 17 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Participants are individuals diagnosed with drug-sensitive tuberculosis or drug-resistant tuberculosis receiving short-term treatment regimens (BPaL/BPaLM)
- Participants are aged 17 years or older.
- Participants experience nausea and vomiting after taking antituberculosis drugs.
- Participants are willing to comply with the study schedule until completion and provide written informed consent.
Who cannot join
- Presence of skin lesions at the site where press needles (PN) will be applied
- Participants who experience nausea and vomiting prior to antituberculosis treatment (including comorbidities that may cause nausea and vomiting, such as renal failure and liver disorders)
- Participants with drug-resistant tuberculosis (DR-TB) receiving long-term or individualized treatment regimens
- Participants with diabetes mellitus and a random blood glucose level > 200 mg/dL
- Participants with unstable hemodynamic status
- Participants who have received acupuncture therapy within the last 2 weeks
- Participants with coagulation disorders (platelet count < 50,000/µL)
- Participants with a history of hypersensitivity reactions to previous acupuncture treatment
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Indonesia1 site, 1 recruiting
- Recruiting
RSUP Persahabatan
Jakarta, Jakarta Timur, 13230
KEPK RSUPP, 0214891708
About this study
Official title: Effectiveness and Safety of Auricular Acupuncture for Nausea and Vomiting Side Effects Induced by Anti-Tuberculosis Drugs in Pulmonary TB Patients
This study will look at whether press-needle ear acupuncture can help lower nausea and vomiting caused by antituberculosis medicines in people with pulmonary tuberculosis. Nausea and vomiting are common side effects of tuberculosis treatment, and they can make people stop taking their medicines
When treatment is stopped too early, tuberculosis may not be cured and may become resistant to medicines.
Read more
Participants in this study will have nausea and vomiting related to their tuberculosis treatment. They will be randomly assigned to one of two groups. One group will receive press-needle ear acupuncture. The other group will receive a placebo version that looks similar but does not stimulate acupuncture points
Researchers will check nausea and vomiting scores before treatment, during treatment, and after treatment to see whether press-needle acupuncture works better than placebo and whether it is safe. Press-needle acupuncture may help reduce nausea and vomiting by affecting nerves and lowering certain chemicals that trigger these symptoms, and it has minimal side effects
If this method is proven helpful and safe, it may give patients a comfortable and low-risk way to manage nausea and vomiting during tuberculosis treatment
- Conditions
- Tuberculosis, Pulmonary
- Being tested
- Press Needle, Sham Press Needle
- Medical subject headings
- Tuberculosis, Pulmonary
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Press NeedleDevice
Press needle is performed once at bilateral MA-TF1 Shenmen, MA-AH-7 Sympathetic, and MA-IC6 Stomach using Press Needle (Pyonex® 0,17x0,9 mm). Standard aseptic procedures are followed. Participants continue their routine pharmacological anti-emetics treatment.
Sham Press NeedleDevice
Press needle is performed once at bilateral MA-TF1 Shenmen, MA-AH-7 Sympathetic, and MA-IC6 Stomach using Sham Press Needle. Standard aseptic procedures are followed. Participants continue their routine pharmacological anti-emetics treatment.
| Study group | Role | What they receive |
|---|---|---|
| Press Needle Group | Experimental | Press Needle Receives: Device: Press Needle |
| Sham Press Needle Group | Sham comparator | Sham Press Needle Receives: Device: Sham Press Needle |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rhodes indeks of nausea, vomiting, and retching (RINVR)
a validated patient-reported questionnaire used to measure the severity and impact of nausea, vomiting, and retching. It consists of eight items that evaluate the frequency, duration, and distress associated with these symptoms over a specific time period. Each item is scored using a Likert scale, and the total score reflects the overall symptom burden.
Measured: Baseline, 1 day, 3 days, 7 days, 10 days, 14 days after intervention
Secondary outcomes (1)
Adverse Events Related to Intervention
Any adverse events occurring after the intervention, including infection, pain, or skin irritation at the insertion site, will be monitored and recorded.
Measured: 1 day, 3 days, 7 days, 10 days, 14 days after intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Dec 2025
- Study start5 Nov 2025
- Primary completion1 Jun 2026 (estimated)
- Study completion30 Jun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Tuberculosis, PulmonaryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The intervention group will receive press needle, while the control group will receive sham press needle
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 58 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Universitas Indonesia
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Kevin Supratman, Universitas Indonesia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07271225
- Sponsor's protocol ID
- 0215
- Status last verified
- Nov 2025
- First submitted
- 27 Nov 2025
- Last updated
- 9 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No